SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950123-11-056529
Filing Date
2011-06-03
Accepted
2011-06-06 09:08:47
Documents
1
Period of Report
2011-06-01
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K y91572e8vk.htm 8-K 17202
  Complete submission text file 0000950123-11-056529.txt   18723
Mailing Address P.O. BOX 110526 RESEARCH TRIANGLE PARK NC 27709
Business Address 4101 RESEARCH COMMONS 79 T.W. ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 919-316-6300
Talecris Biotherapeutics Holdings Corp. (Filer) CIK: 0001405197 (see all company filings)

IRS No.: 202533768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34473 | Film No.: 11894005
SIC: 2834 Pharmaceutical Preparations